Varicella-Zoster Virus (VZV)

Practice Essentials

Varicella-zoster virus (VZV) is an alpha herpes virus that causes chickenpox and herpes zoster (shingles).^[1]  Varicella is characterized by a maculopapular, vesicular rash that can be pruritic and evolves into dried crusts (scabs) over a 3- to 7-day period.^{[2, 3]}  Reactivation of the dormant virus results in the characteristic painful dermatomal rash of herpes zoster, which is often followed by pain in the distribution of the rash (postherpetic neuralgia). 

Chicken pox is considered contagious beginning 1-2 days before rash onset until all lesions have crusted (scabbed).  

View Image

Typical zoster in the vicinity of right popliteal fossa in a vertebral nerve L4 distribution.

Signs and symptoms

Chicken pox

In children, chicken pox manifests with fever and irritability, followed by vesicular rash eruption. The rash eventually crusts and heals. 

Chicken pox also can occur in adults without natural or vaccine induced immunity to VZV. 

Herpes zoster (shingles)

• The most common presentation is the shingles vesicular rash, which most commonly affects a thoracic dermatome. Pain and paresthesia typically are the first symptoms of VZV infection. Until the characteristic vesicular rash erupts, diagnosis may be difficult. A prodromal period during which symptoms may vary is common. 
• After a prodromal illness of pain and paresthesias, erythematous macules and papules develop and progress to vesicles. 
• The vesicles eventually crust and resolve.
• Pain and sensory loss are the usual symptoms.
• Motor weakness also may occur and frequently is missed on examination.
• Cases of actual monoplegia due to VZV brachial plexus neuritis have been reported.

Zoster multiplex

• Shingles may appear in multiple dermatomes, both contiguous and noncontiguous, on either side of the body.
• Immunocompromised individuals are more susceptible.
• Terminology depends on the number of involved dermatomes and on whether the condition is unilateral or bilateral (eg, zoster duplex unilateralis refers to the involvement of two unilateral dermatomes)
• Cases of zoster simultaneously occurring in seven noncontiguous dermatomes have been reported

Zoster sine herpete

Varicella-zoster virus infection may reactivate without causing cutaneous vesicles. These patients have severe dermatomal pain, possible motor weakness, and possible hypesthesia, but no visible rash or vesicles.

Varicella-zoster virus infection may present as acute peripheral facial palsy in 8-25% of patients who have no cutaneous vesicles. This is more common in immunosuppressed patients who use acyclovir (or other agents) as zoster prophylaxis.^[4]

Central nervous system disease

• VZV continues to be associated with CNS disease, with meningitis being the most frequent clinical presentation. A 2011 study found CNS VZV disease often presented without accompanying zoster rash.^[5]

Ramsay-Hunt syndrome

This syndrome occurs when the geniculate ganglion is involved.^[6] The clinical presentation includes the following:

• A peripheral facial palsy
• Pain in the ear and face
• Vesicles in the external ear canal (not always present)
• Additional auditory and vestibular symptoms in some cases

Keratitis (herpes ophthalmicus)

• Herpes ophthalmicus is caused by reactivation of VZV infection in the ophthalmic division of the trigeminal nerve.
• The presentation may include conjunctivitis or corneal ulcers.
• Complications include blindness.
• Vesicles do not have to be present.
• Rarely, the virus migrates along the intracranial branches of the trigeminal nerve, causing thrombotic cerebrovasculopathy with severe headache and hemiplegia.

See Clinical Presentation for more detail.

Diagnosis

Diagnosis of chicken pox or herpes Zoster is typically clinical. 

If in doubt laboratory tests can be performed. PCR to detect VZV DNA is the most reliable and sensitive method. Direct immunofluorescence (DFA) to detect VZV antigen is the second choice; only 60–70% of cases are detectable by PCR. Other methods can be used to confirm VZV infection that are less preferable and less commonly used. Viral culture of VZV is possible but is insensitive, time-consuming, and expensive because it requires special media.

• In cases of acyclovir-resistant VZV, detections of mutations in thymidine kinase can be determined by PCR and sequence analysis.
• MRI may be useful if myelitis, meningitis, or encephalitis is suspected.
• Lumbar puncture may be helpful if signs suggest myelitis, meningitis, or encephalitis.

See Workup for more detail.

Management

Treatment options are based on the following:

• Patient age
• Patient immune state
• Duration of symptoms
• Presentation

Antiviral medications decrease symptom duration and the likelihood of postherpetic neuralgia, especially when initiated within 2 days of the onset of rash. Oral acyclovir may be prescribed in otherwise healthy patients who have typical cases. Compared with oral acyclovir, other medications (eg, valacyclovir, penciclovir, famciclovir) may decrease the duration of the patient's pain.

Varicella-zoster immune globulin (VariZIG) is indicated for administration to high-risk individuals within 10 days (ideally within 4 days) of chickenpox (VZV) exposure.^[7] High-risk groups include the following:

• Immunocompromised children and adults
• Newborns of mothers with varicella shortly before or after birth
• Premature infants
• Infants younger than 1 year
• Adults without evidence of immunity
• Pregnant individuals

See Treatment and Medication for more detail.

• References

Background

Varicella-zoster virus is the cause of chickenpox and herpes zoster (also called shingles). Chickenpox follows initial exposure to the virus and typically is a relatively mild, self-limited childhood illness with a characteristic vesicular rash.

Approximately 1 per 4000 children develops VZV encephalitis, an acute neurologic disorder with potentially severe complications. In addition, immunocompromised children (eg, those receiving chemotherapy for leukemia or those with advanced HIV infection) can develop disseminated VZV infection, a potentially fatal complication.^[8]

After primary infection, VZV remains dormant in sensory nerve roots for life. Upon reactivation, the virus migrates down the sensory nerve to the skin, causing the characteristic painful dermatomal rash. After resolution, many individuals continue to experience pain in the distribution of the rash (postherpetic neuralgia). In addition, reactivation of VZV infection can cause a spectrum of atypical presentations, ranging from self-limited radicular pain without rash to spinal cord disease with weakness.

• References

Pathophysiology

Varicella-zoster virus is a human alphaherpesvirus that causes varicella (chickenpox) as the primary infection and establishes latency in sensory ganglia. Infectious virus is transmitted by aerosolized respiratory droplets or by contact with virus in varicella or zoster skin lesions. Varicella-zoster virus in respiratory or conjunctival mucosal cells can interact with and infect local immune system cells and those in adjacent lymphoid tissues. Chickenpox rash develops after an incubation period of 10 to 21 days.^[9]

The host immunologic mechanisms suppress replication of the virus. Reactivation can occur if host immune mechanisms are compromised. This may be caused by medications, illness, malnutrition, stress, or by the natural decline in immune function with aging. Upon reactivation, the virus migrates along sensory nerves and produces sensory loss, pain, and other neurologic complications. If motor nerve roots are also involved, weakness can develop in addition to sensory changes. Leptomeningeal involvement is rare but may develop when the ophthalmic branch of the trigeminal nerve is involved.

• References

Frequency

United States

Varicella used to be very common in the United States. In the early 1990s, an average of 4 million people got varicella, 10,500 to 13,000 were hospitalized, and 100 to 150 died each year. Since introduction of the varicella vaccination program in 1995 in the United States, varicella morbidity (cases and hospitalizations) and mortality (deaths) have decreased by more than 90%.

Per CDC report, the incidence of herpes zoster is approximately 4 cases per 1,000 US population annually. The incidence among people 60 years and older is about 1 case per 100 US population annually. 

An estimated one million cases of HZ occur annually in the United States. 

A meta-analysis of 69 studies from various countries found a cumulative incidence of HZ ranging from 2.9 to 19.5 cases per 1,000 population and an incidence rate of HZ ranging from 5.23 to 10.9 cases per 1,000 person-years. Studies revealed a trend of increasing incidence of HZ with increasing age and over time.^[10]

• References

Mortality/Morbidity

About 95% of patients with zoster experience severe pain during the illness. The risk of developing post herpetic neuralgia in patients with HZ varies from 5% to more than 30%, as recently reported in a systematic review of 130 studies in 26 countries.^[11] The occurrence of both HZ and PHN increases with age.

Other presentations of zoster, including ocular (keratitis) and spinal cord (myelitis) presentations, may result in additional morbidity.

Bacterial superinfection (impetiginization) of vesicular skin lesions can occur.

Severe complications include secondary bacterial infections (most notably those caused by group A beta-hemolytic Streptococcus, eg, cellulitis, necrotizing fasciitis, septicemia, and toxic shock syndrome), pneumonia, encephalitis, cerebellar ataxia, Reye syndrome, and death.^{[8, 12]}

• References

Epidemiology

The cumulative incidence (3.22–11.2 vs 2.44–8.0 cases per 1000 population) and incidence rates (6.05–12.8 vs 4.30–8.5 cases per 1000 person-years) were higher in females than males. Studies revealed a trend of increasing incidence of HZ with increasing age and over time.^[10]

Zoster mortality is presumably elevated in countries severely affected by the HIV/AIDS pandemic.

The lifetime risk of developing HZ is between 25% and 30%, rising to 50% in those aged at least 80 years. The estimated average overall incidence of HZ is about 3.4–4.82 per 1000 person years, which increases to more than 11 per 1000 person years in those aged at least 80 years.^[13]

• References

Prognosis

Since the varicella vaccination program was implemented in 1995, hospitalizations and deaths from varicella have declined in the United States by 93% and 94%, respectively.

• References

History

Pain and paresthesia are typically the first symptoms. Until the characteristic vesicular rash erupts, diagnosis may be difficult.^[3]

A prodromal period during which symptoms may vary is common. Pain occurs in 41% of patients, itching in 27%, and paresthesias in 12%.

During the acute illness, 90% of patients experience pain, 20% describe helplessness and depression, and 12% experience flulike symptoms.

• References

Physical

Herpes zoster (shingles)

The most common presentation is the shingles vesicular rash, which most commonly affects a thoracic dermatome.

After a prodromal illness of pain and paresthesias, erythematous macules and papules develop and progress to vesicles in 1-2 days. The vesicles eventually crust and resolve.

Pain and sensory loss are the usual symptoms, but motor weakness also occurs and is frequently missed on examination. Motor weakness results when the viral activity extends beyond the sensory root to involve the motor root. Cases of actual monoplegia due to varicella-zoster virus (VZV) brachial plexus neuritis have been reported.

View Image

Typical zoster in the vicinity of right popliteal fossa in a vertebral nerve L4 distribution.

View Image

Human herpesvirus (HHV) type 3. Intraoral herpes zoster closely resembles recurrent HHV-1 infection, but the lesions generally follow a dermatome and ....

Zoster multiplex

Shingles may appear in multiple dermatomes, both contiguous and noncontiguous, on either side of the body.

They are more common in individuals who are immunocompromised.

Terminology depends on the number of involved dermatomes and on whether the condition is unilateral or bilateral. For example, zoster duplex unilateralis refers to the involvement of two unilateral dermatomes. Cases of zoster simultaneously occurring in seven noncontiguous dermatomes have been reported.

Zoster sine herpete

Varicella-zoster virus infection may reactivate without causing cutaneous vesicles. These patients have severe dermatomal pain, possible motor weakness and possible hypesthesia, but no visible rash or vesicles.

Studies show that VZV infection may present as acute peripheral facial palsy in 8-25% of patients who have no cutaneous vesicles. This is more common in immunosuppressed patients who use acyclovir (or other agents) as zoster prophylaxis.^[4]

Myelitis

Varicella-zoster virus infection may also cause central nervous system deficits.

Although deficits are more common in immunocompromised individuals, such presentations do occur in the general population.

In one report, the condition began as a typical shingles rash, but spinal cord involvement became apparent 3 weeks after the onset of the initial rash.

The manifestations are usually bilateral. The physical findings may progress.

The underlying pathology typically progresses for 3 or more weeks. Progression for 6 months in immunocompromised individuals has been reported.

With intravenous acyclovir treatment, most cases fully resolve. Recurrence is rare but has been reported.

Zoster encephalitis is also rare but is reported in otherwise healthy individuals. Due to the effectiveness of two-dose vaccinations, fewer cases of VZV encephalitis occur,^[14] yet most cases in vaccinated individuals are due to wild type from the vaccine strain.^[15]

Ramsay-Hunt syndrome

This syndrome occurs when the geniculate ganglion is involved.^[6]

The clinical presentation includes a peripheral facial palsy, pain in the ear and face, and vesicles in the external ear canal.

Additional auditory and vestibular symptoms may be present. The vesicles are not present in all cases.

Keratitis (herpes ophthalmicus)

This is caused by reactivation of VZV infection in the ophthalmic division of the trigeminal nerve.

The presentation may include conjunctivitis or corneal ulcers. Complications include blindness.

The vesicles do not have to be present.

Rarely, in cases of herpes ophthalmicus, the virus migrates along the intracranial branches of the trigeminal nerve, causing thrombotic cerebrovasculopathy with severe headache and hemiplegia.

• References

Causes

Immunosuppression increases the risk for both typical shingles and atypical presentations, such as myelitis, encephalitis, disseminated disease, and visceral involvement.

• References

Laboratory Studies

Confirmation methods for lab testing are the following:

• PCR to detect VZV DNA from the base of a deroofed vesicular lesion is the most reliable and sensitive method, and is now considered the gold standard. False-negative PCR results are more likely to occur from lesions in vaccinated persons.
• Direct immunofluorescence (DFA) to detect VZV antigen is the second choice; sensitivity is only 60–70% of cases detectable by PCR.
• Viral culture of VZV is possible but is insensitive, time-consuming, and expensive because it requires special media.
• Serologic tests may be used to confirm disease but are less reliable than PCR or DFA for virus identification. A fourfold or greater rise in serum varicella IgG titers from acute- and convalescent-phase samples indicates a recent VZV infection. However, persons in whom vaccination produced a high VZV IgG titer may not achieve the required fourfold increase in the convalescent sample. Serologic tests are also less useful in immunocompromised people who are less likely to mount an effective immune response. Testing for VZV IgM by using commercial kits is not recommended because available methods lack sensitivity and specificity. 

• References

Imaging Studies

MRI may be useful if myelitis or encephalitis is suspected.

• References

Procedures

Lumbar puncture may be helpful if signs suggest myelitis or encephalitis. The cerebrospinal fluid (CSF) shows increased levels of protein and pleocytosis because the inflammatory response involves the leptomeninges. CSF PCR can be used to detect VZV DNA.

Although seldom necessary, biopsy results provide a definitive diagnosis.

• References

Histologic Findings

The varicella zoster virus is a DNA virus with a genome that encodes 70 proteins.

The Tzanck preparation shows characteristic findings of giant cells with two to 15 nuclei. Recently infected epithelial cells contain a single enlarged nucleus with a thick nuclear membrane.

After reactivation, meningeal biopsy samples show a local inflammatory response, consisting of plasma cells and lymphocytes, that encompasses the leptomeninges.

Evidence has shown that motor neuron involvement is demyelinating rather than axonal.

• References

Medical Care

Therapy should be initiated at the earliest sign or symptom of herpes zoster and is most effective when started generally within 72h of the onset of zoster rash.

Treatment options are based on the patient's age, immune state, duration of symptoms, and presentation.

Several studies indicate that antiviral medications decrease symptom duration and the likelihood of postherpetic neuralgia, especially when initiated within 2 days of the onset of rash. In typical cases that involve individuals who are otherwise healthy, oral acyclovir may be prescribed. An important study by Kubeyinje (1997) suggested that the use of acyclovir in healthy young adults with zoster is not clearly justified, especially in situations of limited economic resources.^[16]

Acyclovir has two limitations—bioavailability and the existence of some resistant strains of varicella-zoster virus (VZV).

Other medications, including valacyclovir, penciclovir, and famciclovir, are available. They may have an increasing role in the treatment of typical zoster. Studies suggest that, when compared with oral acyclovir, the new medications may decrease the duration of the patient's pain.

Zoster confined to dermatome (immunocompetent or immunocompromised patients)^[17] :

• Acyclovir 800 mg PO 5 times daily for 7-10d or famciclovir 500 mg PO TID for 7d or valacyclovir 1000 mg PO TID for 7d

Visceral, central nervous system, or disseminated VZV infections, and zoster in severely immunocompromised patients^[17] :

• Acyclovir 10 mg/kg (500 mg/m² in children < 12 y) IV q8h for 7-10d

Persistent lesions after 7 to 10 days of treatment with acyclovir may suggest acyclovir resistance. There are case reports of treatment with Foscarnet in immune compromised patients.^[18] Infectious disease specialist consultation is recommended in complicated cases. Thymadine Kinase mutation testing and alternative treatment agents may be needed. 

Varicella zoster immune globulin (VariZIG) is indicated for administration to high-risk individuals within 10 days (ideally within 4 days) of chickenpox (varicella zoster virus) exposure.^[7]

In July 2013, the CDC issued updated recommendations for the use of varicella-zoster immune globulin (VariZIG) to reduce the severity of VZV infection, extending the window for postexposure prophylaxis for those at high risk for severe varicella.^{[7, 8, 19]}  The FDA's original approval of VariZIG recommended use within 4 days, but subsequent studies have shown that the treatment is effective for up to 10 days after exposure.

Other recommendations include the use of VariZIG in the following patients:

• Immunocompromised patients without evidence of immunity
• Newborn infants whose mothers have varicella symptoms between 5 days before and 2 days after delivery
• Hospitalized premature infants born at 28 weeks of gestation or later whose mothers do not have evidence of immunity to varicella
• Hospitalized premature infants born at less than 28 weeks of gestation or who weigh less than 1000 g at birth, regardless of their mothers' evidence of immunity to varicella
• Pregnant individuals without evidence of immunity

Dworkin et al (2009) conducted a randomized, placebo-controlled trial of oral oxycodone and oral gabapentin as potential treatments for acute pain in patients with herpes zoster. They found that controlled-release oxycodone was superior to placebo in the early period of pain (1-14 d). Gabapentin was not shown to yield a significantly greater relief of pain than placebo, although it conferred modest pain relief during the first week.^[20]

There is no convincing evidence that use of corticosteroids prevents post herpetic neuralgia. 

• References

Surgical Care

Surgical care may be required for complications of zoster, such as necrotizing fasciitis.

• References

Consultations

Consultation with a neurologist is indicated in cases of myelitis or encephalitis.

Consultation with an infectious disease specialist should be considered if bacterial superinfection or viral resistance to acyclovir are suspected and for recurrent zoster. 

Consultation with an ophthalmologist is indicated upon optic involvement.

Consultation with a dermatologist may be helpful when the rash is atypical.

• References

Prevention

Varicella (chickenpox) vaccine

CDC recommends two doses of varicella (chickenpox) vaccine for children, adolescents, and adults to protect against varicella. Children are routinely recommended to receive the first dose at age 12 through 15 months and the second dose at age 4 through 6 years old.

Herpes zoster (shingles) vaccine

In October 2017, the FDA approved zoster vaccine recombinant, adjuvanted (Shingrix) for the prevention of shingles in adults aged 50 years or older. The approval is based on findings from a phase III clinical trial program assessing its efficacy, safety, and immunogenicity in 38,000 patients. Data from a pooled analysis of two clinical trials demonstrated efficacy against shingles at greater than 90% across all age groups, as well as sustained efficacy over a follow-up period of 4 years.^{[21, 22, 23, 24, 25]}

In February 2018, the CDC approved the 2018 adult immunization schedules. Changes to the 2018 schedule regarding zoster vaccines includes the following^[23] :

• Administer two doses of recombinant zoster vaccine (RZV) (Shingrix) 2-6 months apart to adults aged 50 years or older regardless of past episodes of herpes zoster or receipt of zoster vaccine live (ZVL) (Zostavax).
• Administer two doses of RZV 2-6 months apart to adults who previously received ZVL at least 2 months after ZVL.
• For adults aged 60 years or older, administer either RZV or ZVL (RZV is preferred).

Combined measles, mumps, rubella, and varicella (MMRV) vaccine

Updated guidelines were issued in June 2009 by the CDC's Advisory Committee on Immunization Practices (ACIP) concerning the use of the combined measles, mumps, rubella, and varicella vaccine (MMRV, ProQuad, Merck & Co, Inc).^{[26, 27, 28, 29]} The MMRV vaccine, which was approved in the United States in September 2005, can be used as an alternative to the separate measles, mumps, rubella vaccine (MMR, M-M-RII, Merck & Co, Inc) and varicella vaccine (VARIVAX, Merck & Co, Inc) to fulfill the recommended two-dose vaccination schedule aimed at preventing measles, mumps, rubella, and varicella in children aged 12 months to 12 years. Initially, the MMRV vaccine was the preferred choice for both the first and second doses instead of individual injections of the MMR and varicella vaccines. This preference aligned with the ACIP's 2006 general recommendations on the use of combination vaccines (CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices [ACIP]. 

• References

Guidelines Summary

The following organizations have released guidelines for the management of varicella-zoster virus. Key diagnostic and treatment recommendations have been reviewed and integrated throughout the article.  

• US Centers for Disease Control and Prevention (2024): Clinical guidance for people at risk for severe varicella.^[8]
• Advisory Committee on Immunization Practices (2024): Varicella (chickenpox) vaccine.^[30]
• Advisory Committee on Immunization Practices (2018): Use of herpes zoster vaccines.^[21]
• US Centers for Disease Control and Prevention (2018): Recommended immunization schedule for adults aged 19 years and older in the United States.^[23]
• US Centers for Disease Control and Prevention (updated in 2013): Use of VariZIG in the United States.^[7]
• Advisory Committee on Immunization Practices (2010): Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine.^[26]

• References

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to prevent complications. Current research is considering whether the varicella vaccine may also prove efficacious as treatment for active varicella-zoster virus (VZV) infection.

• References

Acyclovir (Zovirax)

• Dosing, Interactions, etc.

Clinical Context:  Patients experience less pain and faster resolution of cutaneous lesions when used within 48 h from rash onset. May prevent recurrent outbreaks.

• References

Valacyclovir (Valtrex)

• Dosing, Interactions, etc.

Clinical Context:  Prodrug rapidly converted to the active drug acyclovir. More expensive but has a more convenient dosing regimen than acyclovir.

• References

Famciclovir (Famvir)

• Dosing, Interactions, etc.

Clinical Context:  Prodrug that, when biotransformed into active metabolite penciclovir, may inhibit viral DNA synthesis/replication.

• References

Class Summary

Three medications may help reduce pain and symptoms and the incidence of postherpetic neuralgia. All need to be used with caution in patients with renal compromise. Hemolytic uremic syndrome is rare but has been reported. All 3 agents may be used for 7-10 d, depending on response. Only acyclovir is available in an intravenous form.

• References

Varicella virus vaccine (Varivax)

• Dosing, Interactions, etc.

Clinical Context:  A live attenuated varicella virus prepared from the Oka/Merck strain. It is propagated in human diploid cell cultures (MRC-5). Each 0.5-mL dose (when reconstituted) contains 1350 PFU of varicella, sucrose, and gelatin; residual components of MRC-5 DNA and protein; and trace quantities of neomycin and fetal bovine serum. Indicated for vaccination against varicella in individuals >1 y.

• References

Class Summary

These agents are used to induce active immunity.

The combined MMRV vaccine (ProQuad) is associated with an increased risk for febrile seizure occurring 5-12 days after vaccination at a rate of 1 in 2300-2600 in children aged 12-23 months compared with separate MMR vaccine and varicella vaccine administered simultaneously.^{[27, 28]}

As a result, the CDC Advisory Committee on Immunization Practices (ACIP) recommends that separate MMR and varicella vaccines be used for the first dose, although providers or parents may opt to use the combined MMRV for the first dose after counseling regarding this risk.^[29]

MMRV is preferred for the second dose (at any age) or the first dose if given at age 48 months or older.

Data from post-licensure studies do not suggest that children aged 4-6 years who received the second dose of MMRV vaccine had an increased risk for febrile seizures after vaccination compared with children the same age who received MMR vaccine and varicella vaccine administered as separate injections at the same visit.^[29]

• References

Zoster vaccine recombinant (Shingrix)

• Dosing, Interactions, etc.

Clinical Context:  Non-live recombinant subunit vaccine intended for IM injection in 2 doses. It consists of glycoprotein E, an antigen, and AS01B, an adjuvant system, intended to induce a strong and sustained immune response to help overcome reduced immunity that comes with age. Indicated for the prevention of shingles (herpes zoster) in adults aged 50 years or older.

• References

Class Summary

These agents are used to induce active immunity.

In October 2017, the FDA approved zoster vaccine recombinant, adjuvanted (Shingrix) for the prevention of shingles in adults aged 50 years or older. The approval is based on findings from a phase III clinical trial program assessing its efficacy, safety, and immunogenicity in 38,000 patients. Data from a pooled analysis of two clinical trials demonstrated efficacy against shingles at greater than 90% across all age groups, as well as sustained efficacy over a follow-up period of 4 years.^{[22, 24]}

• References

Capsaicin transdermal patch (Qutenza)

• Dosing, Interactions, etc.

Clinical Context:  Transient receptor potential vanilloid-1 (TRPV1) agonist indicated for neuropathic pain associated with postherpetic neuralgia. TRPV1 is an ion channel–receptor complex expressed on nociceptive skin nerve fibers. Topical capsaicin causes initial TRPV1 stimulation that may cause pain, followed by pain relief by reduction in TRPV1-expressing nociceptive nerve endings. Neuropathic pain may gradually recur over several months (thought to be caused by TRPV1 nerve fiber reinnervation of treated area).

• References

Class Summary

Topical analgesics that contain capsaicin are effective in decreasing neuropathic pain caused by postherpetic neuralgia.

• References

Varicella zoster immune globulin, human (VariZIG)

• Dosing, Interactions, etc.

Clinical Context:  Varicella zoster immune globulin (VZIG) contains immunoglobulin G (IgG) varicella-zoster antibodies. It provides passive immunization to exposed individuals at high risk of complications from varicella. High- risk groups include immunocompromised children and adults, newborns of mothers with varicella shortly before or after delivery, premature infants, infants < 1 year, adults without evidence of immunity, and pregnant women. Administer by deep IM injection, preferably in deltoid muscle. For neonates or infants, administer IM in anterolateral aspect of thigh.

• References

Class Summary

The specific immune globulin with IgG varicella zoster antibodies provides passive immunization for susceptible individuals when administered within 10 days (ideally within 96 hours) of exposure.

• References

Further Outpatient Care

Typical cases of zoster may be treated in the outpatient setting.

Initial evaluation should address the possibility of atypical manifestations.

• References

Further Inpatient Care

Patients with ocular involvement may be treated in the hospital.

Inpatient treatment may be appropriate for people who develop complications.

The main patient complaint is pain.

Inpatient treatment is appropriate for immunocompromised people or those with atypical presentations, including myelitis.

• References

Deterrence/Prevention

In May 1995, the American Academy of Pediatrics reviewed the literature on the safety and effectiveness of varicella vaccine and recommended that all susceptible children and adolescents without a contraindication receive routine varicella vaccination. They reaffirmed this recommendation in January 2000. However, many logistic and financial barriers have prevented the widespread adoption of this recommendation.

Both clinical varicella and zoster may occur despite vaccination. However, in 3 large studies, vaccination was 100% effective in preventing severe disease.

A study by Tseng et al examined the risk of herpes zoster in patients who underwent vaccination.^[25] Among older adults (>60 y), a lower incidence rate was noted.

In March 2011, the Food and Drug Administration (FDA) lowered the approved age for use of Zostavax to 50-59 years. Zostavax was already approved for use in individuals aged 60 years or older. Annually, in the United States, shingles affects approximately 200,000 healthy people aged 50-59 years. Approval was based on a multicenter study, the Zostavax Efficacy and Safety Trial (ZEST).^[31] The trial was conducted in the United States and 4 other countries in 22,439 people aged 50-59 years. Participants were randomized in a 1:1 ratio to receive either Zostavax or placebo. Participants were monitored for at least 1 year to see if shingles developed. Compared with placebo, Zostavax significantly reduced the risk of developing zoster by approximately 70%.

The virus was found in the saliva of individuals who received the zoster vaccine; persons older than 60 years shed virus in their saliva for as long as 4 weeks after vaccination.^[32]

Severe herpes zoster has been described as a rare complication of varicella vaccination in immunocompetent young children, with these children at low risk of developing meningoencephalitis.^[33] In children, VZV infection may produce a facial palsy^[34] ; it may also result in zoster sine herpete, more so in children than in adults. Ramsay Hunt syndrome (herpes zoster oticus) tends to develop more often in school-aged children, while zoster sine herpete is more likely to develop in preschool children.

• References

Complications

In cases of typical zoster, both streptococcal and staphylococcal superinfections are common potential complications. With ocular, spinal cord, or other involvement, permanent injury is a risk. With ocular involvement, the patient may require long-term antiviral treatment. One study suggests that trigeminal distribution and advanced age increase risk of complications.^[35]

Other complications include the following:

• Necrotizing fasciitis
• Gastrointestinal complications
• Fatal hemorrhagic encephalitis
• Motor weakness
• Postherpetic neuralgia (most common) (The underlying pathophysiology of the condition may involve peripheral nerve injury or continued viral activation without rash, similar to zoster sin herpete.)
• Vasculopathy

• References

Prognosis

Postherpetic neuralgia remains the most common complication of varicella-zoster virus (VZV) infection reactivation, affecting up to 50% of the patients older than 60 years. Most cases are temporary, but many cases persist chronically, impairing productivity and quality of life.

A landmark study by Rowbotham and Fields (1996) shows no clear relationship between loss of peripheral nerve function and postherpetic neuralgia pain.^[36] Although many mechanisms may cause the pain, this study helps explain the efficacy of topical agents such as capsaicin or lidocaine patches.

As evidence of the complexity of the issue, Oaklander and colleagues (1998) examined patients with postherpetic neuralgia and found bilateral damage in patients with unilateral shingles. Neurite loss was noted in the contralateral homologous region in test subjects who experienced no pain and had no history of shingles.^[37]

Many treatment options are available for postherpetic neuralgia.

• Oral medications
• Topical preparations
• Gamma knife procedures
• Jaipur blocks

• References